Cardiac Safety with High Cumulative Dose of Pegylated Liposomal Doxorubicin in Patients with Metastatic Breast Cancer Previously Treated with Conventional Anthracyclines  

作　　者：Ahmed Refaat Dalia O. Mohamed Elsayed Mostafa Ali Salah Mabrouk Khallaf Ahmed Refaat;Dalia O. Mohamed;Elsayed Mostafa Ali;Salah Mabrouk Khallaf(Medical Oncology Department, South Egypt Cancer Institute, Assiut University, Assiut, Egypt;Radiation Oncology Department, South Egypt Cancer Institute, Assiut University, Assiut, Egypt;Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Sohag, Egypt)

机构地区：[1]Medical Oncology Department, South Egypt Cancer Institute, Assiut University, Assiut, Egypt [2]Radiation Oncology Department, South Egypt Cancer Institute, Assiut University, Assiut, Egypt [3]Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Sohag, Egypt

出　　处：《Advances in Breast Cancer Research》2020年第3期55-65,共11页乳腺癌（英文）

摘　　要：<strong>Introduction:</strong> <span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">The treatment of metastatic breast cancer (MBC) is still challenging.</span></span></span><span><span><span style="font-family:""> </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">Many studies documented the efficacy of</span></span></span><span><span><span style="font-family:""> </span></span></span><span><span><span style="font-family:""><span style="font-family:Verdana;">pegylated liposomal doxorubicin (PLD) in patients with MBC, but there is a limited data about the cardiac safety with high cumulative dose (HCD) of PLD. </span><b><span style="font-family:Verdana;">Aim of the work:</span></b></span></span></span><span><span><span style="font-family:""> </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">We conducted this trial to outline the cardiac safety of HCD of PLD in patients </span></span></span><span><span><span style="font-family:""><span style="font-family:Verdana;">with MBC who previously received conventional anthracyclines. </span><b><span style="font-family:Verdana;">Methods:</span></b> <span style="font-family:Verdana;">During the period of nine years (January 2011 to December 2019). We extracted</span><span style="font-family:Verdana;"> the data of the patients with MBC receiving PLD at Medical Oncology Department, South Egypt Cancer Institute, Assiut University. These included patients’ demographics and therapeutic data including the full data of PLD, prior conventional anthracyclines, prior trastuzumab, and prior radiotherapy. Also, data about comorbidities as well as cardiac and other toxicities of PLD were obtained. The data was analysed using SPSS v. 21. </span><b><span style="font-family:Verdana;">Results:</span></b><span style="font-family:Verdana;"> For all 81 eligible patients, the mean age was 43.9 ye<strong>Introduction:</strong> <span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">The treatment of metastatic breast cancer (MBC) is still challenging.</span></span></span><span><span><span style="font-family:""> </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">Many studies documented the efficacy of</span></span></span><span><span><span style="font-family:""> </span></span></span><span><span><span style="font-family:""><span style="font-family:Verdana;">pegylated liposomal doxorubicin (PLD) in patients with MBC, but there is a limited data about the cardiac safety with high cumulative dose (HCD) of PLD. </span><b><span style="font-family:Verdana;">Aim of the work:</span></b></span></span></span><span><span><span style="font-family:""> </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">We conducted this trial to outline the cardiac safety of HCD of PLD in patients </span></span></span><span><span><span style="font-family:""><span style="font-family:Verdana;">with MBC who previously received conventional anthracyclines. </span><b><span style="font-family:Verdana;">Methods:</span></b> <span style="font-family:Verdana;">During the period of nine years (January 2011 to December 2019). We extracted</span><span style="font-family:Verdana;"> the data of the patients with MBC receiving PLD at Medical Oncology Department, South Egypt Cancer Institute, Assiut University. These included patients’ demographics and therapeutic data including the full data of PLD, prior conventional anthracyclines, prior trastuzumab, and prior radiotherapy. Also, data about comorbidities as well as cardiac and other toxicities of PLD were obtained. The data was analysed using SPSS v. 21. </span><b><span style="font-family:Verdana;">Results:</span></b><span style="font-family:Verdana;"> For all 81 eligible patients, the mean age was 43.9 ye

关 键 词：Metastatic Breast Cancer Pegylated Liposomal Doxorubicin High Cumulative Dose Cardiac Toxicity 

分 类 号：O17[理学—数学]